Company / Cash & Equivalents
Inhibikase Therapeutics, Inc. Cash & Equivalents History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$56.5M
FY2024
5-year range
$7.2M / $56.5M
FY2022-FY2024
Trend
+516.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +516% YoY in FY2024, a notable deviation from the 2-year average annual change of +272%.
Based on SEC 10-K filings.
$57M in FY2024.
Improved from $7M to $57M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, cash & equivalents increased 516.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $56.5M | +516.1% |
| FY2023 | $9.2M | +27.5% |
| FY2022 | $7.2M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026